Pharmalot By Ed Silverman Multiple sclerosis patients see drug value differently than payers and doctors
First Opinion By Brian C. Callaghan and Lindsey De Lott Medicare shouldn’t pay more for drugs when others pay less
Pharmalot By Ed Silverman Insurers pay more for multiple sclerosis drug because rebates don’t help, report says
Exclusive By Sharon Begley Bold claim of multiple sclerosis gene discovery comes under withering attack
In the Lab By Sharon Begley Discovery of multiple sclerosis gene could inspire new therapies — if it’s right